Back to search

France· FR:60397909

REPLAGAL 1 mg/ml, solution à diluer pour perfusion

A agalsidase alfa product containing agalsidase alfa, registered in France by TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE). The same ATC class is registered in 13 of our 19 countries.

ATC A16AB03

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedREPLAGAL 1 mg/ml, solution à diluer p…ATCA16AB03REGISTER NO.FR:60397909PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Agalsidase alfa is registered in 13 of 19 countries.

Countries holding a registration under ATC A16AB03 (agalsidase alfa), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose

Agalsidase alfa · ATC A16AB03

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
AGALSIDASE ALFA
Manufacturer
TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)
Country
France (FR)
ATC code
A16AB03
ATC class
Agalsidase alfa
Defined daily dose
1 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400956340057
    1 flacon(s) en verre de 3,5 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/694642ba-c423-4d8a-8e30-e70856d9ad70
GET /v1/drugs/694642ba-c423-4d8a-8e30-e70856d9ad70?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "60397909",
  "date_amm": "2001-08-03",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/01/189",
  "substance": "AGALSIDASE ALFA",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about agalsidase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.